Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magdalena Hoellwerth

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cancers|January 11, 2024
Prognostic Value of Baseline <sup>18</sup>F-FDG PET/CT to Predict Brain Metastasis Development in Melanoma PatientsForough Kalantari, Seyed Ali Mirshahvalad, Magdalena Hoellwerth, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 14, 2023
The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centresAlexander Troesch, Magdalena Hoellwerth, Stephan Forchhammer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2025
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapyKatharina Schumann, Kai Christian Klespe, Cornelia Mauch, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and SwitzerlandKatharina Schumann, Cornelia Mauch, Kai-Christian Klespe, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cancers|January 11, 2024
Prognostic Value of Baseline <sup>18</sup>F-FDG PET/CT to Predict Brain Metastasis Development in Melanoma PatientsForough Kalantari, Seyed Ali Mirshahvalad, Magdalena Hoellwerth, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 14, 2023
The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centresAlexander Troesch, Magdalena Hoellwerth, Stephan Forchhammer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2025
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapyKatharina Schumann, Kai Christian Klespe, Cornelia Mauch, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and SwitzerlandKatharina Schumann, Cornelia Mauch, Kai-Christian Klespe, et al.
Pageof 2